Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

nc3912 8 posts  |  Last Activity: Feb 2, 2016 11:11 AM Member since: Jul 2, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Potential Per February Results?

    by nc3912 Feb 1, 2016 2:10 PM
    nc3912 nc3912 Feb 2, 2016 11:11 AM Flag

    Thank you for the info. It seems that hepatitis drugs are the only bio stocks anymore that have huge moves on good news.

    Sentiment: Hold

  • I am a newbie to the stock. Is the potential with the RG-101 results in mid-February similar to the Phase 1 results in late 2014? Or is the bio bear market going to put a lid on price appreciation? Thanks.

    Sentiment: Hold

  • Reply to

    IBS-C

    by richinjun Jan 19, 2016 11:28 AM
    nc3912 nc3912 Jan 19, 2016 12:04 PM Flag

    They must expect IBS-C 2 early in the 2nd half if they plan to have the NDA filed by December. I would only be guessing, but maybe April or May on IBS-C 1.

    Sentiment: Buy

  • Reply to

    IBS-C

    by richinjun Jan 19, 2016 11:28 AM
    nc3912 nc3912 Jan 19, 2016 11:41 AM Flag

    No sure what happened there. I know I heard management state at least three different times last year that IBS-C results would be out by the end of Dec.15 or in very early 2016. Most recently, however, they have guided for IBS-C 1 to be released in 1st half 16 and IBS-C 2 in 2nd half. They are still promising a NDA application for IBS-C by the end of this year.

    Sentiment: Buy

  • Reply to

    Feuerstein-Ratain Rule

    by nc3912 Dec 2, 2015 10:27 AM
    nc3912 nc3912 Dec 2, 2015 11:04 AM Flag

    August 11th and August 19 thru the 26th (weekends included) were days with a closing price of $4.19 or lower. The remaining days were above $4.20

    Sentiment: Buy

  • Adam Feuerstein mentioned in his column this morning that Threshold did not meet the Feuerstein-Ratain Rule which concludes that oncology companies with market caps below $300 million do not ever succeed with Phase 3 trials. The data is measured 4 months prior to announcement of results. If you go back and look at trading in August (4 months prior to this month), Threshold actually closed at or above $4.20 on 13 of 21 trading days. $4.20 per share is equivalent to a $300 million market cap for Threshold. This one is really on the cusp.

    Sentiment: Buy

  • It's hard to read a lot from a stock's future based on the trading before Phase 3 results. In early March 2009, Dendreon went briefly below $3. Six weeks later when successful Phase 3 results came out, the stock traded above $20. It was not a micro-cap either. At the time, it had around 100 million shares outstanding. The market cap went from $300 million to $2 billion in six weeks.

    Sentiment: Buy

  • nc3912 by nc3912 Nov 13, 2015 12:34 PM Flag

    If THLD achieves statistical significance on just 1 of the 2 Phase 3 trials, we are going to be several dollars higher than we are now. Obviously, if both trials are home runs, we will see a big-time pop. Some of the brokerages have a $14 target. If the trials are successful and the stock is de-risked, you may see those price targets go even higher.

    Sentiment: Buy

AMRN
1.27-0.05(-3.79%)Feb 11 4:00 PMEST